Quarterly ResultApr 29, 2026, 04:44 PM
CNMD Q1 Sales $317.0M (-1.3%); Adj. EPS $0.89; Raises FY26 Organic Rev Outlook
AI Summary
CONMED Corp reported Q1 2026 sales of $317.0 million, a 1.3% decrease year-over-year, primarily due to a $15.5 million impact from the exit of certain GI products. Diluted GAAP EPS was $0.45, while adjusted diluted EPS was $0.89, compared to $0.95 in Q1 2025. Despite the sales decline, the company exceeded expectations and raised its full-year 2026 organic constant currency revenue growth outlook to 5.0%-6.5%, while reaffirming adjusted diluted EPS guidance of $4.30-$4.45.
Key Highlights
- Q1 2026 Sales: $317.0 million, down 1.3% YoY (2.9% constant currency).
- Q1 2026 Diluted GAAP EPS: $0.45, up from $0.19 in Q1 2025.
- Q1 2026 Adjusted Diluted EPS: $0.89, down from $0.95 in Q1 2025.
- Domestic revenue decreased 5.8% YoY, impacted by $15.2M GI product exit.
- International revenue increased 4.7% YoY (1.0% constant currency).
- Orthopedic Surgery sales: $147.7 million, up 6.8% YoY.
- Raises FY26 organic constant currency revenue growth outlook to 5.0%-6.5%.
- Reaffirms FY26 adjusted diluted EPS guidance of $4.30-$4.45.